Risk assessment and implications of MicroRNA-210 on hepatocellular carcinoma patients: a case control study.
MIR-210 in liver cancer
Background: Carcinogenesis in Hepatocellular carcinoma (HCC) is associated with hypoxia and reactive oxygen species (ROS) production. The master hypoxamir, MIRNA-210, is involved in tumor growth, apoptosis, and angiogenesis. MiRNA-210 has been reported to regulate responses and tolerate hypoxia-induced stress. The aim of study is to evaluate circulating miRNA-210 in HCC.
Methods: 60 cirrhotic HCC patients (group I) classified into three sub-groups according to BCLC staging (20 patients each); Group (IA): stages 0/A, (IB): stage B and (IC): stages C/D. Group II comprised 60 cirrhotic patients without HCC. Group III included 60 healthy controls. All participants were evaluated clinically, Circulating MIR-210 expression was assessed by real time polymerase chain reaction.
Results: MIR-210 was higher in group I compared to other groups (P <0.001 in others). MIR-210 was higher in group 1C than other sub-groups (P <0.001).
Conclusions: Significant difference in circulating biomarker MIR-210 between HCC and other groups implies critical role in HCC carcinogenesis.